These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 39204319)

  • 1. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.
    Boersma B; Poinot H; Pommier A
    Pharmaceutics; 2024 Jul; 16(8):. PubMed ID: 39204319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.
    Prodi E; Neri D; De Luca R
    Onco Targets Ther; 2024; 17():697-715. PubMed ID: 39224695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
    Pabani A; Gainor JF
    Clin Cancer Res; 2023 Oct; 29(19):3841-3849. PubMed ID: 37227449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine/Antibody Fusion Protein Design and Evaluation.
    Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
    Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive correlation between VCA-IgM and Th1/Th2 immunocytokines in children with infectious mononucleosis.
    Yang D; Gong Z; Ye C; Huang H; Liu Y; Bai B
    Am J Transl Res; 2022; 14(10):7578-7584. PubMed ID: 36398262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming the limitations of cytokines to improve cancer therapy.
    Di Trani CA; Cirella A; Arrizabalaga L; Fernandez-Sendin M; Bella A; Aranda F; Melero I; Berraondo P
    Int Rev Cell Mol Biol; 2022; 369():107-141. PubMed ID: 35777862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice.
    Lutz EA; Jailkhani N; Momin N; Huang Y; Sheen A; Kang BH; Wittrup KD; Hynes RO
    PNAS Nexus; 2022 Nov; 1(5):pgac244. PubMed ID: 36712341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of IL-2-Fc-antibody conjugates by click chemistry.
    Williams L; Li L; Yazaki PJ; Wong P; Miller A; Hong T; Poku EK; Bhattacharya S; Shively JE; Kujawski M
    Biotechnol J; 2023 Sep; 18(9):e2300115. PubMed ID: 37300381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytokines: amplification of anti-cancer immunity.
    Davis CB; Gillies SD
    Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytokines: a review of molecules in clinical development for cancer therapy.
    List T; Neri D
    Clin Pharmacol; 2013; 5(Suppl 1):29-45. PubMed ID: 23990735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.